SARMS LGD 4033

SARMs LGD-4033, also known as Ligandrol, is a 3rd generation non-steroidal oral SARM with a high affinity for the androgen receptor (Ki of ~1 nM). It is currently the second most popular SARM on the market. Unlike testosterone which exerts anabolic effects by the same pathway, LGD-4033 has high selectivity for receptors in skeletal muscle, bone, and connective tissue, with minimal affinity for receptors in the prostate, scalp and skin.
It was developed by Ligand Pharmaceuticals to treat conditions such as muscle wasting and osteoporosis without the virilizing side effects of anabolic steroids. LGD 4033 is considered by many researchers to be the best SARM for producing lean body mass. Sports Technology Labs is the best place to buy LGD-4033 online.
LGD 4033 Benefits from Clinical Research
Muscle Mass
Preclinical primate data showed a significant quantity-dependent increase in lean body mass for male and female monkeys during 13 weeks at either 0.6, 3, 15, or 75 MG/KG of bodyweight. In addition to this, 70% of the increased body mass was retained after a 4 week recovery period.
Only the 75mg/kg group stopped testing after 48 days due to toxicity. This quantity is significantly higher than the highest quantity administered in clinical trials.
Bone Recovery
A Phase 1 clinical trial with 76 adult males orally administered LGD-4033 at varying quantities showed a quantity-dependent increase in lean body mass and was well tolerated by all 76 subjects for 21 days. Phase 2 clinical trials consisted of 120 subjects recovering from hip fracture surgery. The subjects either received a placebo, 0.5, 1, or 2mg LGD-4033 over 12 weeks.
All quantities of LGD-4033 created significant increases in total lean body mass and subjects exhibited quantity dependent decreases in mean fat mass.
Subjects administered LGD-4033 showed improvements in serum procollagen type 1 propeptide (s-P1NP), a marker of bone anabolism, and improvements in 6-minute walk distance as compared to placebo. No significant adverse effects were reported in any of the study groups.
Subjects were assessed 12 weeks after completion of the trial, at which they maintained the muscle mass that they had gained from the drug.